Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities investigation

Pomerantz Investigates Dr. Reddy's Securities Fraud Claims

Analysis based on 9 articles · First reported Aug 25, 2026 · Last updated Sep 10, 2026

Sentiment
-10
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The investigation adds legal uncertainty for Abbott Laboratories, potentially leading to further stock price volatility and reputational damage. Broader market impact is limited as this is a company-specific legal matter within the pharmaceutical sector.

pharmaceuticals legal services

Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories Limited regarding potential securities fraud or other unlawful business practices. The investigation stems from Dr. Reddy's announcement on July 22, 2026 of its first quarter fiscal 2027 earnings, which reported earnings per share of only $0.06, adversely impacted by a 2.4 billion rupee provision related to out-of-specification semaglutide batches. CEO Erez Israeli stated that the quarter's EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives and other associated costs. Following this news, Dr. Reddy's stock price fell $1.18 per share, or 9.4%, to close at $11.38 per share on July 22, 2026. Pomerantz LLP, a law firm specializing in corporate, securities, and antitrust class litigation, is advising affected investors to contact them regarding potential participation in a class action. The investigation concerns whether Dr. Reddy's and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices.

80 Abbott Laboratories maintained FY27 outlook
70 Abbott Laboratories saw share decline
60 Pomerantz LLP investigating claims Abbott Laboratories
stock
Subject of the securities fraud investigation following disappointing Q1 FY2027 earnings and a significant provision for rejected semaglutide batches, which caused a 9.4% stock drop.
Importance 95.0 Sentiment -40.0
priv
Law firm conducting the investigation on behalf of investors, potentially leading to a class action lawsuit against Dr. Reddy's.
Importance 80.0 Sentiment 0.0
per
CEO of Dr. Reddy's, quoted explaining the earnings miss and semaglutide-related challenges; his statements are central to the investigation.
Importance 60.0 Sentiment -20.0
exch
Exchange where Dr. Reddy's stock is listed and traded; the 9.4% price drop occurred on this exchange.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.